May 8 |
Zevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ...
|
May 8 |
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
|
May 8 |
Zevra Therapeutics GAAP EPS of -$0.40 beats by $0.08, revenue of $3.42M misses by $0.34M
|
May 8 |
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
|
May 7 |
Zevra Therapeutics Q1 2024 Earnings Preview
|
May 2 |
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
|
May 1 |
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
|
Apr 29 |
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
|
Apr 15 |
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
|
Apr 10 |
Zevra Therapeutics retires existing debt with new $100M credit facility
|